English  |  正體中文  |  简体中文  |  Total items :0  
Visitors :  51148433    Online Users :  642
Project Commissioned by the Ministry of Education
Project Executed by National Taiwan University Library
 
臺灣學術機構典藏系統 (Taiwan Academic Institutional Repository, TAIR)
About TAIR

Browse By

News

Copyright

Related Links

"ann lii cheng"

Return to Browse by Author
Sorting by Title Sort by Date

Showing items 446-470 of 690  (28 Page(s) Totally)
<< < 13 14 15 16 17 18 19 20 21 22 > >>
View [10|25|50] records per page

Institution Date Title Author
臺大學術典藏 2021-08-31T06:29:37Z Health-related quality of life in a randomised phase III study of gemcitabine plus S-1, S-1 alone and gemcitabine alone for locally advanced or metastatic pancreatic cancer: GEST study Hagiwara Y.; Ohashi Y.; Okusaka T.; Ueno H.; Ioka T.; Boku N.; Egawa S.; Hatori T.; Furuse J.; Mizumoto K.; Ohkawa S.; Yamaguchi T.; Yamao K.; Funakoshi A.; ANN-LII CHENG; Kihara K.; Sato A.; Tanaka M.
臺大學術典藏 2021-08-31T06:29:37Z Corrigendum to ��Degradation of Epidermal Growth Factor Receptor Mediates Dasatinib-Induced Apoptosis in Head and Neck Squamous Cell Carcinoma Cells�� [Neoplasia (United States) 14 (2012) 463�V475](S1476558612801023)(10.1596/neo.12300) Lin Y.-C.; Wu M.-H.; Wei T.-T.; Chuang S.-H.; Chen K.-F.; ANN-LII CHENG; Chen C.-C.
臺大學術典藏 2021-08-31T06:29:36Z mRECIST to predict survival in advanced hepatocellular carcinoma: Analysis of two randomised phase II trials comparing nintedanib vs sorafenib Meyer T.; Palmer D.H.; ANN-LII CHENG; Hocke J.; Loemb? A.-B.; Yen C.-J.
臺大學術典藏 2021-08-31T06:29:36Z Early perfusion changes within 1 week of systemic treatment measured by dynamic contrast-enhanced MRI may predict survival in patients with advanced hepatocellular carcinoma Chen B.-B.; Hsu C.-Y.; Yu C.-W.; Liang P.-C.; Hsu C.; Hsu C.-H.; ANN-LII CHENG; Shih T.T.-F.
臺大學術典藏 2021-08-31T06:29:36Z Corrigendum to ��Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma�� (Journal of Hepatology (2017) 66(3) (666�V668) (S0168827816307127) (10.1016/j.jhep.2016.12.007)) Tai W.-T.; ANN-LII CHENG; Shiau C.-W.; Huang H.-P.; Huang J.-W.; Chen P.-J.; Chen K.-F.
臺大學術典藏 2021-08-31T06:29:36Z Updated results from GEST study: a randomized, three-arm phase III study for advanced pancreatic cancer Okusaka T.; Miyakawa H.; Fujii H.; Nakamori S.; Satoh T.; Hamamoto Y.; Ito T.; Maguchi H.; Matsumoto S.; Ueno H.; Ioka T.; Boku N.; Egawa S.; Hatori T.; Furuse J.; Mizumoto K.; Ohkawa S.; Yamaguchi T.; Yamao K.; Funakoshi A.; Chen J.S.; ANN-LII CHENG; Sato A.; Ohashi Y.; Tanaka M.; on behalf of the GEST group
臺大學術典藏 2021-08-31T06:29:35Z National policies fostering hospice care increased hospice utilization and reduced the invasiveness of end-of-life care for cancer patients Shao Y.-Y.; Hsiue E.H.-C.; Hsu C.-H.; Yao C.-A.; Chen H.-M.; Lai M.-S.; ANN-LII CHENG
臺大學術典藏 2021-08-31T06:29:35Z Association of MDM2 expression with shorter progression-free survival and overall survival in patients with advanced pancreatic cancer treated with gemcitabine-based chemotherapy Yang S.-H.; Lee J.-C.; Guo J.-C.; Kuo S.-H.; Tien Y.-W.; Kuo T.-C.; ANN-LII CHENG; Yeh K.-H.
臺大學術典藏 2021-08-31T06:29:35Z Asia�VPacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update Omata M.; ANN-LII CHENG; Kokudo N.; Kudo M.; Lee J.M.; Jia J.; Tateishi R.; Han K.-H.; Chawla Y.K.; Shiina S.; Jafri W.; Payawal D.A.; Ohki T.; Ogasawara S.; Chen P.-J.; Lesmana C.R.A.; Lesmana L.A.; Gani R.A.; Obi S.; Dokmeci A.K.; Sarin S.K.
臺大學術典藏 2021-08-31T06:29:34Z High plasma interleukin-6 levels associated with poor prognosis of patients with advanced hepatocellular carcinoma Shao Y.-Y.; Lin H.; Li Y.-S.; Lee Y.-H.; Chen H.-M.; ANN-LII CHENG; Hsu C.-H.
臺大學術典藏 2021-08-31T06:29:34Z Lenalidomide as second-line therapy for advanced hepatocellular carcinoma: exploration of biomarkers for treatment efficacy Shao Y.-Y.; Chen B.-B.; Ou D.-L.; Lin Z.-Z.; Hsu C.-H.; Wang M.-J.; ANN-LII CHENG; Hsu C.
臺大學術典藏 2021-08-31T06:29:34Z A role of multimodality bladder-preserving therapy in patients with muscle-invasive bladder cancer plus hydronephrosis with or without pelvic nodal involvement Chiang Y.; Cheng J.C.-H.; Huang C.-Y.; Tsai Y.-C.; Lin C.-C.; Hsu C.-H.; ANN-LII CHENG; Pu Y.-S.
臺大學術典藏 2021-08-31T06:29:33Z Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies Bruix J.; ANN-LII CHENG; Meinhardt G.; Nakajima K.; De Sanctis Y.; Llovet J.
臺大學術典藏 2021-08-31T06:29:33Z Phosphatidylinositol-3 Kinase Inhibitors, Buparlisib and Alpelisib, Sensitize Estrogen Receptor-positive Breast Cancer Cells to Tamoxifen Chen I.-C.; Hsiao L.-P.; Huang I.-W.; Yu H.-C.; Yeh L.-C.; Lin C.-H.; Wei-Wu Chen T.; ANN-LII CHENG; Lu Y.-S.
臺大學術典藏 2021-08-31T06:29:33Z Hepatitis C virus core protein potentiates proangiogenic activity of hepatocellular carcinoma cells Shao Y.-Y.; Hsieh M.-S.; Wang H.-Y.; Li Y.-S.; Lin H.; Hsu H.-W.; Huang C.-Y.; Hsu C.-H.; ANN-LII CHENG
臺大學術典藏 2021-08-31T06:29:32Z Immunomodulatory Effects of Current Targeted Therapies on Hepatocellular Carcinoma: Implication for the Future of Immunotherapy Lin Y.-Y.; Tan C.-T.; Chen C.-W.; Ou D.-L.; ANN-LII CHENG; Hsu C.
臺大學術典藏 2021-08-31T06:29:32Z The HER2 inhibitor lapatinib potentiates doxorubicininduced cardiotoxicity through iNOS signaling Hsu W.-T.; Huang C.-Y.; Yen C.Y.T.; ANN-LII CHENG; Hsieh P.C.H.
臺大學術典藏 2021-08-31T06:29:32Z Orantinib versus placebo combined with transcatheter arterial chemoembolisation in patients with unresectable hepatocellular carcinoma (ORIENTAL): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study Kudo M.; ANN-LII CHENG; Park J.-W.; Park J.H.; Liang P.-C.; Hidaka H.; Izumi N.; Heo J.; Lee Y.J.; Sheen I.-S.; Chiu C.-F.; Arioka H.; Morita S.; Arai Y.
臺大學術典藏 2021-08-31T06:29:32Z First-line antibiotic therapy in Helicobacter pylori-negative low-grade gastric mucosa-associated lymphoid tissue lymphoma Kuo S.-H.; Yeh K.-H.; Wu M.-S.; Lin C.-W.; Wei M.-F.; Liou J.-M.; Wang H.-P.; Chen L.-T.; ANN-LII CHENG
臺大學術典藏 2021-08-31T06:29:31Z Recent developments of c-Met as a therapeutic target in hepatocellular carcinoma Bouattour M.; Raymond E.; Qin S.; ANN-LII CHENG; Stammberger U.; Locatelli G.; Faivre S.
臺大學術典藏 2021-08-31T06:29:31Z Reply to: ��Predictors of sorafenib benefit in patients with hepatocellular carcinoma�� Bruix J.; ANN-LII CHENG; Llovet J.
臺大學術典藏 2021-08-31T06:29:31Z Targeting histone deacetylase 4/ubiquitin-conjugating enzyme 9 impairs DNA repair for radiosensitization of hepatocellular carcinoma cells in mice Tsai C.-L.; Liu W.-L.; Hsu F.-M.; Yang P.-S.; Yen R.-F.; Tzen K.-Y.; ANN-LII CHENG; Chen P.-J.; Cheng J.C.-H.
臺大學術典藏 2021-08-31T06:29:30Z Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial Kudo M.; Finn R.S.; Qin S.; Han K.-H.; Ikeda K.; Piscaglia F.; Baron A.; Park J.-W.; Han G.; Jassem J.; Blanc J.F.; Vogel A.; Komov D.; Evans T.R.J.; Lopez C.; Dutcus C.; Guo M.; Saito K.; Kraljevic S.; Tamai T.; Ren M.; ANN-LII CHENG
臺大學術典藏 2021-08-31T06:29:30Z A Phase I/II study of the combination of lapatinib and oral vinorelbine in HER2-positive metastatic breast cancer Chen T.W.-W.; Yeh D.-C.; Chao T.-Y.; Lin C.-H.; Chow L.W.-C.; Chang D.-Y.; Hsieh Y.-Y.; Huang S.-M.; ANN-LII CHENG; Lu Y.-S.; Taiwan Breast Cancer Consortium
臺大學術典藏 2021-08-31T06:29:29Z Targeting tumor-infiltrating Ly6G+ myeloid cells improves sorafenib efficacy in mouse orthotopic hepatocellular carcinoma Chang C.-J.; Yang Y.-H.; Chiu C.-J.; Lu L.-C.; Liao C.-C.; Liang C.-W.; Hsu C.-H.; ANN-LII CHENG

Showing items 446-470 of 690  (28 Page(s) Totally)
<< < 13 14 15 16 17 18 19 20 21 22 > >>
View [10|25|50] records per page